{"nctId":"NCT00737568","briefTitle":"Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine","startDateStruct":{"date":"2008-09"},"conditions":["Hepatitis B"],"count":280,"armGroups":[{"label":"Tenofovir DF","type":"EXPERIMENTAL","interventionNames":["Drug: TDF","Drug: FTC/TDF Placebo"]},{"label":"FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: FTC/TDF","Drug: TDF Placebo"]}],"interventions":[{"name":"TDF","otherNames":["Viread®"]},{"name":"FTC/TDF","otherNames":["Truvada®"]},{"name":"TDF Placebo","otherNames":[]},{"name":"FTC/TDF Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months\n* 18 through 75 years of age, inclusive\n* HBV DNA ≥ 10\\^3 IU/mL\n* Receiving treatment with lamivudine with confirmation of HBV reverse transcriptase mutation(s) known to confer resistance to lamivudine (rtM204I/V with or without rtL180M) by central laboratory assessment prior to randomization; adefovir dipivoxil treatment of ≤ 48 weeks at the time of screening (inclusive of combination adefovir dipivoxil + lamivudine at entry) was allowed\n* Willing and able to provide written informed consent\n* Negative serum pregnancy test (for females of childbearing potential only)\n* Calculated creatinine clearance ≥ 50 mL/min\n* Hemoglobin ≥ 10 g/dL\n* Neutrophils ≥ 1000 /mm\\^3\n* No prior oral HBV therapy with approved nucleotide and/or nucleoside therapy or other investigational agents for HBV infection other than lamivudine or adefovir dipivoxil\n\nExclusion Criteria\n\n* Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study\n* Males and females of reproductive potential who are not willing to use an effective method of contraception during the study\n* Alanine aminotransferase (ALT) ≥ 10 × the upper limit of the normal range (ULN)\n* Decompensated liver disease\n* Interferon or pegylated interferon therapy within 6 months of the screening visit\n* Alpha fetoprotein \\> 50 ng/mL\n* Evidence of hepatocellular carcinoma\n* Coinfection with hepatitis C virus, HIV, or hepatitis D virus\n* Significant renal, cardiovascular, pulmonary, or neurological disease\n* Received solid organ or bone marrow transplantation\n* Receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion\n* Proximal tubulopathy\n* Known hypersensitivity to the study drugs, the metabolites or formulation excipients","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.4","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 144, 192, and 240","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"84.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"85.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"82.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, 192, and 240","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"77.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null},{"groupId":"OG001","value":"84.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]}]},{"type":"SECONDARY","title":"HBV DNA Level at Weeks 48, 96, 144, 192, and 240","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"0.542"},{"groupId":"OG001","value":"2.48","spread":"0.887"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"0.254"},{"groupId":"OG001","value":"2.28","spread":"0.241"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"0.173"},{"groupId":"OG001","value":"2.29","spread":"0.541"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"0.135"},{"groupId":"OG001","value":"2.23","spread":"0.027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"0.052"},{"groupId":"OG001","value":"2.26","spread":"0.376"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Normal ALT at Weeks 48, 96, 144, 192, and 240","description":"Normal ALT was defined as having a value less than or equal to the ULN. The ULN was 43 U/L for males and 34 U/L for females aged 18 to \\< 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","spread":null},{"groupId":"OG001","value":"69.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null},{"groupId":"OG001","value":"69.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null},{"groupId":"OG001","value":"75.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.9","spread":null},{"groupId":"OG001","value":"76.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBeAg Loss at Weeks 48, 96, 144, 192, and 240","description":"The percentage of participants who were HBeAg positive at baseline and who had HBeAg Loss at the given time point was summarized. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, 192, and 240","description":"The percentage of participants who were HBeAg positive at baseline and who had seroconversion to anti-HBe at the given time point was summarized. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, 192, and 240","description":"The percentage of participants with HBsAg Loss at the given time point was summarized. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Weeks 48, 96, 144, 192, and 240","description":"The percentage of participants with seroconversion to anti-HBs at the given time point was summarized. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Breakthrough at Weeks 48, 96, 144, 192, and 240","description":"The percentage of participants with virologic breakthrough at the given time point was summarized. Virologic breakthrough was defined as having two consecutive 1.0 log10 or greater increases in serum HBV DNA from on-treatment nadir, or two consecutive HBV DNA values ≥ 400 copies/mL after being \\< 400 copies/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density (BMD) of the Spine at Weeks 24, 48, 72, 96, 144, 192, and 240","description":"BMD is calculated as grams per cubic centimeter (g/cm\\^2); the mean (SD) percentage change is presented.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"2.867"},{"groupId":"OG001","value":"-1.83","spread":"2.565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"3.094"},{"groupId":"OG001","value":"-1.73","spread":"2.944"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"3.337"},{"groupId":"OG001","value":"-1.95","spread":"2.977"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"3.761"},{"groupId":"OG001","value":"-1.72","spread":"3.269"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"3.810"},{"groupId":"OG001","value":"-1.63","spread":"3.591"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"4.237"},{"groupId":"OG001","value":"-1.60","spread":"4.628"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"4.490"},{"groupId":"OG001","value":"-1.15","spread":"5.130"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in BMD of the Hip at Weeks 24, 48, 72, 96, 144, 192, and 240","description":"BMD is calculated as g/cm\\^2; the mean (SD) percentage change is presented.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"1.724"},{"groupId":"OG001","value":"-0.59","spread":"1.835"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"2.120"},{"groupId":"OG001","value":"-1.00","spread":"2.063"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"2.507"},{"groupId":"OG001","value":"-1.61","spread":"2.525"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.70","spread":"2.617"},{"groupId":"OG001","value":"-1.77","spread":"2.801"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"3.030"},{"groupId":"OG001","value":"-1.91","spread":"3.281"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":"3.190"},{"groupId":"OG001","value":"-2.41","spread":"3.783"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.46","spread":"3.191"},{"groupId":"OG001","value":"-2.63","spread":"3.872"}]}]}]},{"type":"SECONDARY","title":"Development of Drug-resistant Mutations (DRMs)","description":"The development of DRMs was summarized, either as development of new DRMs or enrichment of existing DRMs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":141},"commonTop":["Nasopharyngitis","Headache","Fatigue","Arthralgia","Back pain"]}}}